All News
Dr Aggarwal @docrota et al. Abatacept RCT in IIM. Overall negative trial. Pre-specified and post-hoc analyses suggest some benefit in PM/ANM but not in DM @RheumNow #EULAR2022 POS0839 https://t.co/uttMLKy9fW
Richard Conway RichardPAConway ( View Tweet)
Palmowski et al. Glucocorticoids and bone density in GCA/PMR/other vasculitis from Rh-GIOP. Weird one, no increase in osteoporosis, no association with current or cumulative steroid dose and osteoporosis. Low BMI, vert #, PPIs were assoc osteoporosis. @RheumNow #EULAR2022 POS1139 https://t.co/n3d6YArXmU
Richard Conway RichardPAConway ( View Tweet)
The two forms of Axial PsA - classical (Axial SpA like) and alternative. Plenary session today #EULAR2022 by Prof. Philip Helliwell. I will be discussing this further in my vlog @RheumNow https://t.co/hxAhgMhHlJ
Dr. Antoni Chan synovialjoints ( View Tweet)
Quote of the day “Don’t be too quick to call it negative” by Marco Gattorno on looking for systemic Autoinflammatory disease (SAID) when there is the clinical suspicion #EULAR2022 @RheumNow https://t.co/SjARIlDjtR
Dr. Antoni Chan synovialjoints ( View Tweet)
Agree. Love to understand:
- standardisation for whole body MRI
- how it does not compromise image quality vs limited field
- clear explanation of benefit vs limited field, where it exists
Its inappropriate use in the worried well by charlatans has skewed me #EULAR2022 @RheumNow https://t.co/3LRz0OOAEF
David Liew drdavidliew ( View Tweet)
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Richard Conway RichardPAConway ( View Tweet)
Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM
Richard Conway RichardPAConway ( View Tweet)
Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
De Miguel et al. Subclinical GCA in PMR shows different US pattern to classic GCA. Less cranial involvement and more isolated extra-cranial. About what you would have expected given clinical manifestations. @RheumNow #EULAR2022 POS0248 https://t.co/i9IZBdF1vQ
Richard Conway RichardPAConway ( View Tweet)
Joanna Robson @Robsonjo4 et al. Disease specific outcome measure for GCA (badly needed!) GCA-PROM. Demonstrated internal and external validity in measuring health related quality of life in GCA patients. @RheumNow #EULAR2022 POS0003 https://t.co/F8pLvlzqD1
Richard Conway RichardPAConway ( View Tweet)
Please see my video interview with Dr @LucyCarter6 on her prize winning #EULAR2022 abstract #OP0234 on transcriptomic analyses of peripheral bloods in identifying modules that predict OR protect progression from ANA+ to #lupus or CTD @RheumNow https://t.co/c3khwFzx79
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT
Richard Conway RichardPAConway ( View Tweet)
Tillett et al. Baseline characteristics and achievement of MDA at week 24 with IL23i guselkumab in bDMARD experienced patients. Pattern of joint (wrist vs shoulder/hand) and skin (scalp vs hand/foot) involvement, as well as male sex, predictive @RheumNow #EULAR2022 POS1051 https://t.co/lHOTgMWgMA
Richard Conway RichardPAConway ( View Tweet)
den Broeder et al. Follow-up to REDO study. Ultra-low dose RTX non-inferior for DAS28CRP. 1000mg 2.2 (2.0-2.4), 500mg 2.2 (2.1-2.4), 200mg 2.3 (2.2-2.5) (all given 6-monthly). Small effect by received dose though (0.15 per 1000mg) @RheumNow #EULAR2022 POS0652 https://t.co/hfSw9ndQpk
Richard Conway RichardPAConway ( View Tweet)
Sousa et al. Anti-Ku disease. Cluster analysis (Ku alone, Ku with other abs) asking is is a distinct entity. In isolated anti-Ku+ maybe so, characterised by Raynauds (41%), arthritis (26%), sicca (26%), myositis (15%), ILD (15%) @RheumNow #EULAR2022 POS0861 https://t.co/IboWzMYFMB
Richard Conway RichardPAConway ( View Tweet)
Video: What Patients Want and Are Willing to Risk with SLE
Dr. Kathryn Dao discusses abstract POS0086 at #EULAR2022 which looks at real life lupus patient preferences who are willing to undergo risk in order to get the treatment outcome that they desire.
https://t.co/kHZz5MrZi2 https://t.co/XRsoXHR1ce
Links:
Dr. John Cush RheumNow ( View Tweet)
Campaniello et al. Ultra-low dose RTX (500/1000mg once a year) vs low dose RTX (500/1000mg 6-monthly) for maintenance in AAV. Comparable relapse free survival 22.7% vs 21.2%, lower severe infection 10.5% vs 26.8% @RheumNow #EULAR2022 POS0837 https://t.co/uBgEmhLUzv
Richard Conway RichardPAConway ( View Tweet)
Prof McInnes @IainBMcInnes1 et al. IL23i guselkumab efficacy maintained irrespective of baseline characteristics of patients. I kind of wish in some of these studies that we would see big differences to help us select between agents! @RheumNow #EULAR2022 POS0072 https://t.co/zJWvpwcDkt
Richard Conway RichardPAConway ( View Tweet)
WIN-Lupus is no winner. Stopping #MMF or #Azathioprine after 2 to 3 yrs of well controlled #SLE is a loser due to more #lupus nephritis. Diff from RCT of MMF taper in remission pts. @RheumNow @eular_org #EULAR2022 https://t.co/Ut8uRonrNP
Janet Pope Janetbirdope ( View Tweet)
Dr Terrier @TerrierBen Mepolizumab gives clinical benefit in EGPA in terms of remission at week 36/48 and accrued remission. Benefit irrespective of presence of vasculitic features, ANCA status, clinical features, etc @RheumNow #EULAR2022 POS0836 https://t.co/GHwt1WNZEs
Richard Conway RichardPAConway ( View Tweet)